PD Dr. Markus Hecht

Medizinische Fakultät Department of Radiation Oncology

Highlights from the 2021 ASCO and ESMO annual meetings on radiotherapy of head and neck cancer Highlights der ASCO- und ESMO-Jahrestagungen 2021 zur Strahlentherapie von Kopf-Hals-Tumoren (2022) Hecht M, von der Grün J, Semrau S, Müller S, Weissmann T, Gaipl U, Iro H, et al. Journal article, Review article The COVID-19 pandemic and its consequences for the diagnosis and therapy of head and neck malignancies (2022) Rupp R, de Vasconcelos Craveiro A, Allner M, Grundtner P, Eckstein M, Hecht M, Iro H, et al. Journal article Baseline Quality of Life of Physical Function Is Highly Relevant for Overall Survival in Advanced Rectal Cancer (2022) Fitz T, Sörgel C, Rutzner S, Hecht M, Fietkau R, Distel L Journal article Influence of gender on radiosensitivity during radiochemotherapy of advanced rectal cancer (2022) Schuster B, Hecht M, Schmidt M, Haderlein M, Jost T, Büttner-Herold M, Weber K, et al. Journal article Definitive chemoradiotherapy of locally advanced head and neck cancer in combination with immune checkpoint inhibition-new concepts required (2021) Hecht M, Fietkau R, Gaipl U Journal article, Editorial Die Bedeutung der Strahlentherapie im Kontext immer effektiver werdender Systemtherapien beim metastasierten NSCLC – Hinweise aus einer Rezidivanalyse nach Immuncheckpointinhibitoren (2021) Schubert P, Fietkau R, Hecht M Journal article Correction to: Innovative radiation oncology Together—Precise, Personalized, Human: Vision 2030 for radiotherapy & radiation oncology in Germany (Strahlentherapie und Onkologie, (2021), 197, 12, (1043-1048), 10.1007/s00066-021-01843-9) (2021) Krug D, Hecht M, Ebert N, Maurer M, Fleischmann DF, Fokas E, Straube C, et al. Journal article, Erratum Oligometastatic head and neck cancer: Which patients benefit from radical local treatment of all tumour sites? (2021) Weissmann T, Höfler D, Hecht M, Semrau S, Haderlein M, Filimonova I, Frey B, et al. Journal article Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors (2021) Griewing LM, Schweizer C, Schubert P, Rutzner S, Eckstein M, Frey B, Haderlein M, et al. Journal article Relevance of the time interval between surgery and adjuvant radio (chemo) therapy in HPV-negative and advanced head and neck carcinoma of unknown primary (CUP) (2021) Balk M, Rupp R, Mantsopoulos K, Allner M, Grundtner P, Müller-Hübner SKU, Traxdorf M, et al. Journal article